Skip to main content
Fig. 2 | Patient Safety in Surgery

Fig. 2

From: The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the “cytokine storm” in COVID-19 patients: a hypothesis

Fig. 2

Differential modulation of prostaglandins from LPS-stimulated PBMC pre-treated with LMWF5A and other anti-inflammatory compounds. PBMC were incubated with compounds for 1 h, followed by overnight stimulation with 100 ng/mL LPS. PGE2 and 15d-PGJ2 release were determined by ELISA, and percent changes are presented as mean ± SD (N = 3). (* = p < 0.05 versus saline control). Adapted and modified from Thomas et al. 2016 [20]

Back to article page
\